title: Systemic fungal infections: major problems in cancer patients.
abstract: Over the last decade, with increasing use of aggressive chemotherapy and bone marrow transplantation in the treatment of cancer, fungi have emerged as a major pathogen. The prognosis of established systemic fungal infections remains poor, but newer antifungal drugs such as fluconazole are changing the outlook of therapy and prophylaxis considerably.
authors.affiliation: Leukaemia Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
authors.forename: R L
authors.initials: RL
authors.lastname: Powles
authors.forename: J
authors.initials: J
authors.lastname: Mehta
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000150:complications* / Q000188:drug therapy / Q000517:prevention & control; D009369:Neoplasms / Q000628:therapy*; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000517:prevention & control; D011379:Prognosis
chemical_list: D000935:Antifungal Agents; D000970:Antineoplastic Agents; D015725:Fluconazole